2025 Q2 -tulosraportti
223 päivää sitten
‧37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 161 | - | - | ||
| 253 | - | - | ||
| 422 | - | - | ||
| 1 487 | - | - | ||
| 156 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. | 7 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 min sittenAnd he continues: – An advantage of a «club deal» is that one to a greater extent avoids investors who only see it as a trading opportunity, says Wiklund. The greatest interest thus came from abroad. – There are some Norwegian investors involved, but to a limited extent and none of the largest. The main part is international. We received several very large orders, and the rest of the allocation is distributed more broadly, says Wiklund.
·13 min sitten
·10 min sittenCan you summarize?
·2 min sittenThis shouldn't really be possible. I am extremely pleased with the outcome," says Circio CEO Erik Wiklund. Circio is the biotech company that has risen over 1.000 percent on Oslo Børs since the New Year. On Wednesday night, Circio raised 250 million kroner from investors in an oversubscribed share issue. The capital raise was carried out as a so-called "club deal," where a select group of new investors were invited to participate. Read also From 13 mill. to 1.8 bill.: Estimated a 100-fold increase for his own company – became a 140-fold increase After Circio CEO Erik Wiklund believed the company could be valued 100 times higher, the market value has risen from 13 million to 1.8 billion. "Still significant upside," he says now. The share issue was hammered out during Easter week. "Not acting now would almost have been irresponsible. We have had patience for a long time, even though many have pushed for us to do the share issue earlier," says Wiklund. Heavily oversubscribed Pareto Securities was the facilitator for the share issue, which was oversubscribed by more than double – meaning that demand was more than twice as high as the number of shares offered. The subscription price was set at 10.80 kroner per share, which was the closing price on the last trading day before Easter, and 23.1 million new shares were issued. The price corresponds to a discount against the last closing price, but is at the same time 5 percent above the volume-weighted average price for the last five days and 20 percent above the average for the last ten days. Existing shareholders will have the opportunity to participate in a subsequent repair issue to limit dilution. At the same time, management and the board have entered into a lock-up agreement, which means they cannot sell shares for the next six months. "The offer was valid now, not tomorrow" Wiklund points to two main reasons why the share issue was done that way. "Interest is very high. At the same time, the world is volatile, and we didn't know what Donald Trump might do. Several investors were clear that the offer was valid now – not tomorrow. We then assessed that it was best to act quickly and carry it out as a closed process," says Wiklund. The company did not want to take the risk of waiting. "We didn't dare to wait. The share rose sharply yesterday – from 10.80 kroner in the morning to 14.40 on high volume. The volume-weighted average price was around 13 kroner, which was another argument for acting quickly. We didn't know how trading and the market in general would be today," says Wiklund. Few took much He cannot disclose the names of the investors who bought shares, but says it mostly concerns international ones. "It's a mix of professional British, Swedish, American, Irish, and some Norwegian investors. We have tried to attract health-focused investors to strengthen the shareholder base. At the same time, such rapid share issues will also attract investors driven by the strong momentum. It will therefore be a combination of more active "deal investors" and long-term health investors," says Wiklund. He believes the structure also helps to filter investors. "An advantage of a "club deal" is that you largely avoid investors who only see it as a trading opportunity," says Wiklund. The greatest interest thus came from abroad. "There are some Norwegian investors involved, but to a limited extent and none of the largest. The main part is international. We received several very large orders, and the rest of the allocation is more broadly distributed," says Wiklund. Secures financing The share issue entails around 10 percent dilution, but at the same time removes the financing risk from the case. "We are now fully financed and have runway until 2030. This allows us to scale significantly. In practice, this has not been possible for Norwegian biotech companies since the market froze towards the end of 2021, with a few exceptions. The fact that we are also doing this at a premium to the 5-day average is strong," claims Wiklund.
·13 min sittenWill participants in the directed issue be grouped under Pareto in the next shareholder list, or will we know who it actually is that has jumped on the bandwagon?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
223 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 min sittenAnd he continues: – An advantage of a «club deal» is that one to a greater extent avoids investors who only see it as a trading opportunity, says Wiklund. The greatest interest thus came from abroad. – There are some Norwegian investors involved, but to a limited extent and none of the largest. The main part is international. We received several very large orders, and the rest of the allocation is distributed more broadly, says Wiklund.
- ·13 min sitten·10 min sittenCan you summarize?·2 min sittenThis shouldn't really be possible. I am extremely pleased with the outcome," says Circio CEO Erik Wiklund. Circio is the biotech company that has risen over 1.000 percent on Oslo Børs since the New Year. On Wednesday night, Circio raised 250 million kroner from investors in an oversubscribed share issue. The capital raise was carried out as a so-called "club deal," where a select group of new investors were invited to participate. Read also From 13 mill. to 1.8 bill.: Estimated a 100-fold increase for his own company – became a 140-fold increase After Circio CEO Erik Wiklund believed the company could be valued 100 times higher, the market value has risen from 13 million to 1.8 billion. "Still significant upside," he says now. The share issue was hammered out during Easter week. "Not acting now would almost have been irresponsible. We have had patience for a long time, even though many have pushed for us to do the share issue earlier," says Wiklund. Heavily oversubscribed Pareto Securities was the facilitator for the share issue, which was oversubscribed by more than double – meaning that demand was more than twice as high as the number of shares offered. The subscription price was set at 10.80 kroner per share, which was the closing price on the last trading day before Easter, and 23.1 million new shares were issued. The price corresponds to a discount against the last closing price, but is at the same time 5 percent above the volume-weighted average price for the last five days and 20 percent above the average for the last ten days. Existing shareholders will have the opportunity to participate in a subsequent repair issue to limit dilution. At the same time, management and the board have entered into a lock-up agreement, which means they cannot sell shares for the next six months. "The offer was valid now, not tomorrow" Wiklund points to two main reasons why the share issue was done that way. "Interest is very high. At the same time, the world is volatile, and we didn't know what Donald Trump might do. Several investors were clear that the offer was valid now – not tomorrow. We then assessed that it was best to act quickly and carry it out as a closed process," says Wiklund. The company did not want to take the risk of waiting. "We didn't dare to wait. The share rose sharply yesterday – from 10.80 kroner in the morning to 14.40 on high volume. The volume-weighted average price was around 13 kroner, which was another argument for acting quickly. We didn't know how trading and the market in general would be today," says Wiklund. Few took much He cannot disclose the names of the investors who bought shares, but says it mostly concerns international ones. "It's a mix of professional British, Swedish, American, Irish, and some Norwegian investors. We have tried to attract health-focused investors to strengthen the shareholder base. At the same time, such rapid share issues will also attract investors driven by the strong momentum. It will therefore be a combination of more active "deal investors" and long-term health investors," says Wiklund. He believes the structure also helps to filter investors. "An advantage of a "club deal" is that you largely avoid investors who only see it as a trading opportunity," says Wiklund. The greatest interest thus came from abroad. "There are some Norwegian investors involved, but to a limited extent and none of the largest. The main part is international. We received several very large orders, and the rest of the allocation is more broadly distributed," says Wiklund. Secures financing The share issue entails around 10 percent dilution, but at the same time removes the financing risk from the case. "We are now fully financed and have runway until 2030. This allows us to scale significantly. In practice, this has not been possible for Norwegian biotech companies since the market froze towards the end of 2021, with a few exceptions. The fact that we are also doing this at a premium to the 5-day average is strong," claims Wiklund.
- ·13 min sittenWill participants in the directed issue be grouped under Pareto in the next shareholder list, or will we know who it actually is that has jumped on the bandwagon?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 161 | - | - | ||
| 253 | - | - | ||
| 422 | - | - | ||
| 1 487 | - | - | ||
| 156 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. | 7 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
2025 Q2 -tulosraportti
223 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. | 7 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 min sittenAnd he continues: – An advantage of a «club deal» is that one to a greater extent avoids investors who only see it as a trading opportunity, says Wiklund. The greatest interest thus came from abroad. – There are some Norwegian investors involved, but to a limited extent and none of the largest. The main part is international. We received several very large orders, and the rest of the allocation is distributed more broadly, says Wiklund.
- ·13 min sitten·10 min sittenCan you summarize?·2 min sittenThis shouldn't really be possible. I am extremely pleased with the outcome," says Circio CEO Erik Wiklund. Circio is the biotech company that has risen over 1.000 percent on Oslo Børs since the New Year. On Wednesday night, Circio raised 250 million kroner from investors in an oversubscribed share issue. The capital raise was carried out as a so-called "club deal," where a select group of new investors were invited to participate. Read also From 13 mill. to 1.8 bill.: Estimated a 100-fold increase for his own company – became a 140-fold increase After Circio CEO Erik Wiklund believed the company could be valued 100 times higher, the market value has risen from 13 million to 1.8 billion. "Still significant upside," he says now. The share issue was hammered out during Easter week. "Not acting now would almost have been irresponsible. We have had patience for a long time, even though many have pushed for us to do the share issue earlier," says Wiklund. Heavily oversubscribed Pareto Securities was the facilitator for the share issue, which was oversubscribed by more than double – meaning that demand was more than twice as high as the number of shares offered. The subscription price was set at 10.80 kroner per share, which was the closing price on the last trading day before Easter, and 23.1 million new shares were issued. The price corresponds to a discount against the last closing price, but is at the same time 5 percent above the volume-weighted average price for the last five days and 20 percent above the average for the last ten days. Existing shareholders will have the opportunity to participate in a subsequent repair issue to limit dilution. At the same time, management and the board have entered into a lock-up agreement, which means they cannot sell shares for the next six months. "The offer was valid now, not tomorrow" Wiklund points to two main reasons why the share issue was done that way. "Interest is very high. At the same time, the world is volatile, and we didn't know what Donald Trump might do. Several investors were clear that the offer was valid now – not tomorrow. We then assessed that it was best to act quickly and carry it out as a closed process," says Wiklund. The company did not want to take the risk of waiting. "We didn't dare to wait. The share rose sharply yesterday – from 10.80 kroner in the morning to 14.40 on high volume. The volume-weighted average price was around 13 kroner, which was another argument for acting quickly. We didn't know how trading and the market in general would be today," says Wiklund. Few took much He cannot disclose the names of the investors who bought shares, but says it mostly concerns international ones. "It's a mix of professional British, Swedish, American, Irish, and some Norwegian investors. We have tried to attract health-focused investors to strengthen the shareholder base. At the same time, such rapid share issues will also attract investors driven by the strong momentum. It will therefore be a combination of more active "deal investors" and long-term health investors," says Wiklund. He believes the structure also helps to filter investors. "An advantage of a "club deal" is that you largely avoid investors who only see it as a trading opportunity," says Wiklund. The greatest interest thus came from abroad. "There are some Norwegian investors involved, but to a limited extent and none of the largest. The main part is international. We received several very large orders, and the rest of the allocation is more broadly distributed," says Wiklund. Secures financing The share issue entails around 10 percent dilution, but at the same time removes the financing risk from the case. "We are now fully financed and have runway until 2030. This allows us to scale significantly. In practice, this has not been possible for Norwegian biotech companies since the market froze towards the end of 2021, with a few exceptions. The fact that we are also doing this at a premium to the 5-day average is strong," claims Wiklund.
- ·13 min sittenWill participants in the directed issue be grouped under Pareto in the next shareholder list, or will we know who it actually is that has jumped on the bandwagon?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 161 | - | - | ||
| 253 | - | - | ||
| 422 | - | - | ||
| 1 487 | - | - | ||
| 156 | - | - |
Välittäjätilasto
Dataa ei löytynyt